forked from DBCG/connectathon
-
Notifications
You must be signed in to change notification settings - Fork 0
/
measure-EXM125_FHIR4-7.2.000.json
311 lines (311 loc) · 26.1 KB
/
measure-EXM125_FHIR4-7.2.000.json
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
{
"resourceType": "Measure",
"id": "measure-EXM125-FHIR4-7.2.000",
"meta": {
"versionId": "2",
"lastUpdated": "2019-12-26T13:49:07.875-07:00",
"profile": [
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/proportion-measure-cqfm"
]
},
"text": {
"status": "generated",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><table class=\"grid dict\"><tr style=\"vertical-align: top;\"><th scope=\"row\"><b>Id: </b></th><td style=\"padding-left: 25px; padding-right: 25px;\">Measure/measure-exm125-FHIR4</td></tr><tr style=\"vertical-align: top;\"><th rowspan=\"1\" scope=\"row\"><b>Type: </b></th><td style=\"padding-left: 25px; padding-right: 25px;\"><span><br/><span><span style=\"padding-left: 25px;\"><b>system: </b><span>http://hl7.org/fhir/measure-type</span><br/></span><span style=\"padding-left: 25px;\"><b>code: </b><span>process</span></span></span></span></td></tr><tr style=\"vertical-align: top;\"><th rowspan=\"2\" scope=\"row\"><b>Identifier: </b></th><td style=\"padding-left: 25px; padding-right: 25px;\"><b>system: </b><span>http://hl7.org/fhir/cqi/ecqm/Measure/Identifier/cms</span><br/><b>value: </b><span>146</span></td></tr><tr style=\"vertical-align: top;\"><td style=\"padding-left: 25px; padding-right: 25px;\"><b>system: </b><span>http://hl7.org/fhir/cqi/ecqm/Measure/Identifier/nqf</span><br/><b>value: </b><span>0002</span></td></tr><tr style=\"vertical-align: top;\"><th scope=\"row\"><b>Title: </b></th><td style=\"padding-left: 25px; padding-right: 25px;\">Breast Cancer Screening</td></tr><tr style=\"vertical-align: top;\"><th scope=\"row\"><b>Status: </b></th><td style=\"padding-left: 25px; padding-right: 25px;\">active</td></tr><tr style=\"vertical-align: top;\"><th scope=\"row\"><b>Description: </b></th><td style=\"padding-left: 25px; padding-right: 25px;\">Percentage of women 50-74 years of age who had a mammogram to screen for breast cancer</td></tr><tr style=\"vertical-align: top;\"><th scope=\"row\"><b>Purpose: </b></th><td style=\"padding-left: 25px; padding-right: 25px;\">Women 51-74 years of age with a visit during the measurement period</td></tr><tr style=\"vertical-align: top;\"><th rowspan=\"1\" scope=\"row\"><b>Use Context: </b></th><td style=\"padding-left: 25px; padding-right: 25px;\"><p style=\"padding-left: 25px; margin-bottom: 5px;\"><b>code: </b><span>program</span></p><p style=\"padding-left: 25px; margin-bottom: 5px;\"><b>value: </b><br/><span><span style=\"padding-left: 25px;\"><b>text: </b><span>eligibile-provider</span></span></span></p></td></tr><tr style=\"vertical-align: top;\"><th rowspan=\"1\" scope=\"row\"><b>Topic: </b></th><td style=\"padding-right: 25px;\"><span><br/><span><span style=\"padding-left: 25px;\"><b>system: </b><span>http://loinc.org</span><br/></span><span style=\"padding-left: 25px;\"><b>code: </b><span>57024-2</span><br/></span><span style=\"padding-left: 25px;\"><b>display: </b><span>Health Quality Measure Document</span></span></span></span></td></tr><tr style=\"vertical-align: top;\"><th rowspan=\"1\" scope=\"row\"><b>Contributor: </b></th><td style=\"padding-left: 25px; padding-right: 25px;\"><b><span>author</span>: </b><span>National Committee for Quality Assurance</span></td></tr><tr style=\"vertical-align: top;\"><th rowspan=\"5\" scope=\"row\"><b>Related: </b></th><td style=\"padding-left: 25px; padding-right: 25px;\"><p style=\"margin-bottom: 5px;\"><b>type: </b><span>citation</span></p><p style=\"margin-bottom: 5px;\"><b>citation: </b><br/><span>American Cancer Society. 2010. Cancer Facts & Figures 2010. Atlanta: American Cancer Society.</span></p></td></tr><tr style=\"vertical-align: top;\"><td style=\"padding-left: 25px; padding-right: 25px;\"><p style=\"margin-bottom: 5px;\"><b>type: </b><span>citation</span></p><p style=\"margin-bottom: 5px;\"><b>citation: </b><br/><span>National Cancer Institute. 2010. \"Breast Cancer Screening.\" http://www.cancer.gov/cancertopics/pdq/screening/breast/healthprofessional</span></p></td></tr><tr style=\"vertical-align: top;\"><td style=\"padding-left: 25px; padding-right: 25px;\"><p style=\"margin-bottom: 5px;\"><b>type: </b><span>citation</span></p><p style=\"margin-bottom: 5px;\"><b>citation: </b><br/><span>National Business Group on Health. 2011. Pathways to Managing Cancer in the Workplace. Washington: National Business Group on Health.</span></p></td></tr><tr style=\"vertical-align: top;\"><td style=\"padding-left: 25px; padding-right: 25px;\"><p style=\"margin-bottom: 5px;\"><b>type: </b><span>citation</span></p><p style=\"margin-bottom: 5px;\"><b>citation: </b><br/><span>U.S. Preventive Services Task Force (USPSTF). 2009. 1) \"Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement.\" 2) \"December 2009 addendum.\" Ann Intern Med 151(10):716-726.</span></p></td></tr><tr style=\"vertical-align: top;\"><td style=\"padding-left: 25px; padding-right: 25px;\"><p style=\"margin-bottom: 5px;\"><b>type: </b><span>citation</span></p><p style=\"margin-bottom: 5px;\"><b>citation: </b><br/><span>BreastCancer.org. 2012. U.S. Breast Cancer Statistics. www.breastcancer.org/symptoms/understand_bc/statistics.jsp</span></p></td></tr><tr style=\"vertical-align: top;\"><th rowspan=\"1\" scope=\"row\"><b>Library: </b></th><td><p style=\"padding-left: 25px; padding-right: 25px;\"><b>reference: </b><span>Library/library-exm125-FHIR4</span></p></td></tr><tr><th scope=\"row\"><b>Disclaimer: </b></th><td style=\"padding-left: 25px; padding-right: 25px;\">The performance Measure is not a clinical guideline and does not establish a standard of medical care, and has not been tested for all potential applications. THE MEASURE AND SPECIFICATIONS ARE PROVIDED \"AS IS\" WITHOUT WARRANTY OF ANY KIND.</td></tr><tr><th scope=\"row\"><b>Scoring: </b></th><td style=\"padding-left: 25px; padding-right: 25px;\"><span><br/><span><span style=\"padding-left: 25px;\"><b>system: </b><span>http://hl7.org/fhir/measure-scoring</span><br/></span><span style=\"padding-left: 25px;\"><b>code: </b><span>proportion</span></span></span></span></td></tr><tr><th scope=\"row\"><b>Rationale: </b></th><td style=\"padding-left: 25px; padding-right: 25px;\">Breast cancer is one of the most common types of cancers, accounting for a quarter of all new cancer diagnoses for women in the U.S. (BreastCancer.Org, 2011). It ranks as the second leading cause of cancer-related mortality in women, accounting for nearly 40,000 estimated deaths in 2013 (American Cancer Society, 2011). <br> According to the National Cancer Institute's Surveillance Epidemiology and End Results program, the chance of a woman being diagnosed with breast cancer in a given year increases with age. By age 30, it is one in 2,212. By age 40, the chances increase to one in 235, by age 50, it becomes one in 54, and, by age 60, it is one in 25. From 2004 to 2008, the median age at the time of breast cancer diagnosis was 61 years among adult women (Tangka et al, 2010). <br> In the U.S., costs associated with a diagnosis of breast cancer range from $451 to $2,520, factoring in continued testing, multiple office visits, and varying procedures. The total costs related to breast cancer add up to nearly $7 billion per year in the U.S., including $2 billion spent on late-stage treatment (Lavigne et al, 2008; Boykoff et al, 2009).</td></tr><tr><th scope=\"row\"><b>Clinical Recommendation: </b></th><td style=\"padding-left: 25px; padding-right: 25px;\">The U.S. Preventive Services Task Force (USPSTF) recommends biennial screening mammography for women aged 50-74 years (B recommendation). The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms (C recommendation). The Task Force concludes the evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years and older (I statement). <br> U.S. Preventive Services Task Force (2009) <br> Grade: B recommendation. The USPSTF recommends biennial screening mammography for women aged 50 to 74 years. <br> Grade: C recommendation. The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms. <br> Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years or older. <br> Grade: D recommendation. The USPSTF recommends against teaching breast self-examination (BSE). <br> Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older. <br> Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of either digital mammography or magnetic resonance imaging (MRI) instead of film mammography as screening modalities for breast cancer.</td></tr><tr><th scope=\"row\"><b>Guidance: </b></th><td style=\"padding-left: 25px; padding-right: 25px;\">Patient self-report for procedures as well as diagnostic studies should be recorded in 'Procedure, Performed' template or 'Diagnostic Study, Performed' template in QRDA-1. Patient self-report is not allowed for laboratory tests. <br> This measure evaluates primary screening. Do not count biopsies, breast ultrasounds, MRIs or tomosynthesis (3D mammography), because they are not appropriate methods for primary breast cancer screening.</td></tr><tr style=\"vertical-align: top;\"><th scope=\"row\"><b>Group:</b></th><td><p style=\"padding-left: 25px; padding-right: 25px;\"><b>Identifier:</b><br/><span style=\"padding-left: 25px;\"><b>value: </b><span>group-1</span><br/></span></p></td></tr><tr style=\"vertical-align: top;\"><td colspan=\"2\"><table style=\"margin-bottom: 5px; width: 100%\"><tr style=\"vertical-align: top;\"><th rowspan=\"4\" scope=\"row\" style=\"padding-left: 25px;\"><b>Population:</b></th><td><p style=\"margin-bottom: 5px; padding-left: 25px;\"><b>Identifier:</b><br/><span style=\"padding-left: 25px;\"><b>value: </b><span>initial-population-identifier</span><br/></span></p><p style=\"margin-bottom: 5px; padding-left: 25px;\"><b>criteria: </b><span>Initial Population</span></p></td></tr><tr style=\"vertical-align: top;\"><td><p style=\"margin-bottom: 5px; padding-left: 25px;\"><b>Identifier:</b><br/><span style=\"padding-left: 25px;\"><b>value: </b><span>numerator-identifier</span><br/></span></p><p style=\"margin-bottom: 5px; padding-left: 25px;\"><b>criteria: </b><span>Numerator</span></p></td></tr><tr style=\"vertical-align: top;\"><td><p style=\"margin-bottom: 5px; padding-left: 25px;\"><b>Identifier:</b><br/><span style=\"padding-left: 25px;\"><b>value: </b><span>denominator-identifier</span><br/></span></p><p style=\"margin-bottom: 5px; padding-left: 25px;\"><b>criteria: </b><span>Denominator</span></p></td></tr><tr style=\"vertical-align: top;\"><td><p style=\"margin-bottom: 5px; padding-left: 25px;\"><b>Identifier:</b><br/><span style=\"padding-left: 25px;\"><b>value: </b><span>denominator-exclusions-identifier</span><br/></span></p><p style=\"margin-bottom: 5px; padding-left: 25px;\"><b>criteria: </b><span>Denominator Exclusion</span></p></td></tr></table></td></tr><tr><th rowspan=\"4\" scope=\"row\"><b>Supplemental Data:</b></th><td style=\"padding-left: 25px; padding-right: 25px;\"><p style=\"margin-bottom: 5px;\"><b>Identifier:</b><br/><span style=\"padding-left: 25px;\"><b>value: </b><span>sde-ethnicity</span><br/></span></p><p style=\"margin-bottom: 5px;\"><b>usage: </b><span><span><br/><span><span style=\"padding-left: 25px;\"><b>system: </b><span>http://hl7.org/fhir/measure-data-usage</span><br/></span><span style=\"padding-left: 25px;\"><b>code: </b><span>supplemental-data</span></span></span></span></span></p><p style=\"margin-bottom: 5px;\"><b>criteria: </b><span>SDE Ethnicity</span></p></td></tr><tr><td style=\"padding-left: 25px; padding-right: 25px;\"><p style=\"margin-bottom: 5px;\"><b>Identifier:</b><br/><span style=\"padding-left: 25px;\"><b>value: </b><span>sde-payer</span><br/></span></p><p style=\"margin-bottom: 5px;\"><b>usage: </b><span><span><br/><span><span style=\"padding-left: 25px;\"><b>system: </b><span>http://hl7.org/fhir/measure-data-usage</span><br/></span><span style=\"padding-left: 25px;\"><b>code: </b><span>supplemental-data</span></span></span></span></span></p><p style=\"margin-bottom: 5px;\"><b>criteria: </b><span>SDE Payer</span></p></td></tr><tr><td style=\"padding-left: 25px; padding-right: 25px;\"><p style=\"margin-bottom: 5px;\"><b>Identifier:</b><br/><span style=\"padding-left: 25px;\"><b>value: </b><span>sde-race</span><br/></span></p><p style=\"margin-bottom: 5px;\"><b>usage: </b><span><span><br/><span><span style=\"padding-left: 25px;\"><b>system: </b><span>http://hl7.org/fhir/measure-data-usage</span><br/></span><span style=\"padding-left: 25px;\"><b>code: </b><span>supplemental-data</span></span></span></span></span></p><p style=\"margin-bottom: 5px;\"><b>criteria: </b><span>SDE Race</span></p></td></tr><tr><td style=\"padding-left: 25px; padding-right: 25px;\"><p style=\"margin-bottom: 5px;\"><b>Identifier:</b><br/><span style=\"padding-left: 25px;\"><b>value: </b><span>sde-sex</span><br/></span></p><p style=\"margin-bottom: 5px;\"><b>usage: </b><span><span><br/><span><span style=\"padding-left: 25px;\"><b>system: </b><span>http://hl7.org/fhir/measure-data-usage</span><br/></span><span style=\"padding-left: 25px;\"><b>code: </b><span>supplemental-data</span></span></span></span></span></p><p style=\"margin-bottom: 5px;\"><b>criteria: </b><span>SDE Sex</span></p></td></tr></table></div>"
},
"extension": [
{
"url": "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/cqfm-populationBasis",
"valueCode": "boolean"
}
],
"url": "http://hl7.org/fhir/us/cqfmeasures/Measure/measure-exm125-FHIR4",
"identifier": [
{
"use": "official",
"system": "http://hl7.org/fhir/cqi/ecqm/Measure/Identifier/cms",
"value": "125"
},
{
"use": "official",
"system": "http://hl7.org/fhir/cqi/ecqm/Measure/Identifier/nqf",
"value": "0002"
}
],
"version": "7.2.000",
"name": "EXM125",
"title": "Breast Cancer Screening",
"status": "active",
"experimental": true,
"date": "2018-08-31",
"publisher": "National Committee for Quality Assurance",
"contact": [
{
"telecom": [
{
"system": "url",
"value": "http://www.ncqa.org/"
}
]
}
],
"description": "Percentage of women 50-74 years of age who had a mammogram to screen for breast cancer",
"useContext": [
{
"code": {
"code": "program"
},
"valueCodeableConcept": {
"text": "eligible-provider"
}
}
],
"jurisdiction": [
{
"coding": [
{
"system": "urn:iso:std:iso:3166",
"code": "US"
}
]
}
],
"purpose": "Women 51-74 years of age with a visit during the measurement period",
"copyright": "This Physician Performance Measure (Measure) and related data specifications were developed by the National Committee for Quality Assurance (NCQA). NCQA is not responsible for any use of the Measure. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. NCQA holds a copyright in the Measure. The Measure can be reproduced and distributed, without modification, for noncommercial purposes (eg, use by healthcare providers in connection with their practices) without obtaining approval from NCQA. Commercial use is defined as the sale, licensing, or distribution of the Measure for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain. All commercial uses or requests for modification must be approved by NCQA and are subject to a license at the discretion of NCQA. (C) 2012-2017 National Committee for Quality Assurance. All Rights Reserved. Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any third party codes contained in the specifications. CPT(R) contained in the Measure specifications is copyright 2004-2017 American Medical Association. LOINC(R) copyright 2004-2017 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R] ) copyright 2004-2017 International Health Terminology Standards Development Organisation. ICD-10 copyright 2017 World Health Organization. All Rights Reserved.",
"approvalDate": "2016-01-01",
"lastReviewDate": "2016-09-01",
"effectivePeriod": {
"start": "2019-01-01",
"end": "2019-12-31"
},
"topic": [
{
"coding": [
{
"system": "http://loinc.org",
"code": "57024-2",
"display": "Health Quality Measure Document"
}
]
}
],
"relatedArtifact": [
{
"type": "citation",
"citation": "American Cancer Society. 2010. Cancer Facts & Figures 2010. Atlanta: American Cancer Society."
},
{
"type": "citation",
"citation": "National Cancer Institute. 2010. \"Breast Cancer Screening.\" http://www.cancer.gov/cancertopics/pdq/screening/breast/healthprofessional"
},
{
"type": "citation",
"citation": "National Business Group on Health. 2011. Pathways to Managing Cancer in the Workplace. Washington: National Business Group on Health."
},
{
"type": "citation",
"citation": "U.S. Preventive Services Task Force (USPSTF). 2009. 1) \"Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement.\" 2) \"December 2009 addendum.\" Ann Intern Med 151(10):716-726."
},
{
"type": "citation",
"citation": "BreastCancer.org. 2012. U.S. Breast Cancer Statistics. www.breastcancer.org/symptoms/understand_bc/statistics.jsp"
},
{
"type": "depends-on",
"resource": "Library/library-FHIRHelpers-4.0.0"
},
{
"type": "depends-on",
"resource": "Library/library-Hospice-FHIR4-1.0.000"
},
{
"type": "depends-on",
"resource": "Library/library-AdultOutpatientEncounters-FHIR4-1.1.000"
},
{
"type": "depends-on",
"resource": "Library/library-MATGlobalCommonFunctions-FHIR4-4.0.000"
},
{
"type": "depends-on",
"resource": "Library/library-SupplementalDataElements-FHIR4-1.0.0"
}
],
"library": [
"Library/library-EXM125-FHIR4-7.2.000"
],
"disclaimer": "The performance Measure is not a clinical guideline and does not establish a standard of medical care, and has not been tested for all potential applications. THE MEASURE AND SPECIFICATIONS ARE PROVIDED \"AS IS\" WITHOUT WARRANTY OF ANY KIND. Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].",
"scoring": {
"coding": [
{
"system": "http://hl7.org/fhir/measure-scoring",
"code": "proportion"
}
]
},
"type": [
{
"coding": [
{
"system": "http://hl7.org/fhir/measure-type",
"code": "process"
}
]
}
],
"rationale": "Breast cancer is one of the most common types of cancers, accounting for a quarter of all new cancer diagnoses for women in the U.S. (BreastCancer.Org, 2011). It ranks as the second leading cause of cancer-related mortality in women, accounting for nearly 40,000 estimated deaths in 2013 (American Cancer Society, 2011). <br> According to the National Cancer Institute's Surveillance Epidemiology and End Results program, the chance of a woman being diagnosed with breast cancer in a given year increases with age. By age 30, it is one in 2,212. By age 40, the chances increase to one in 235, by age 50, it becomes one in 54, and, by age 60, it is one in 25. From 2004 to 2008, the median age at the time of breast cancer diagnosis was 61 years among adult women (Tangka et al, 2010). <br> In the U.S., costs associated with a diagnosis of breast cancer range from $451 to $2,520, factoring in continued testing, multiple office visits, and varying procedures. The total costs related to breast cancer add up to nearly $7 billion per year in the U.S., including $2 billion spent on late-stage treatment (Lavigne et al, 2008; Boykoff et al, 2009).",
"clinicalRecommendationStatement": "The U.S. Preventive Services Task Force (USPSTF) recommends biennial screening mammography for women aged 50-74 years (B recommendation). The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms (C recommendation). The Task Force concludes the evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years and older (I statement). <br> U.S. Preventive Services Task Force (2009) <br> Grade: B recommendation. The USPSTF recommends biennial screening mammography for women aged 50 to 74 years. <br> Grade: C recommendation. The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms. <br> Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years or older. <br> Grade: D recommendation. The USPSTF recommends against teaching breast self-examination (BSE). <br> Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older. <br> Grade: I Statement. The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of either digital mammography or magnetic resonance imaging (MRI) instead of film mammography as screening modalities for breast cancer.",
"improvementNotation": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/measure-improvement-notation",
"code": "increase"
}
]
},
"guidance": "Patient self-report for procedures as well as diagnostic studies should be recorded in 'Procedure, Performed' template or 'Diagnostic Study, Performed' template in QRDA-1. Patient self-report is not allowed for laboratory tests. <br> This measure evaluates primary screening. Do not count biopsies, breast ultrasounds, MRIs or tomosynthesis (3D mammography), because they are not appropriate methods for primary breast cancer screening.",
"group": [
{
"id": "group-1",
"population": [
{
"code": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/measure-population",
"code": "initial-population",
"display": "Initial Population"
}
]
},
"criteria": {
"language": "text/cql",
"expression": "Initial Population"
}
},
{
"code": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/measure-population",
"code": "numerator",
"display": "Numerator"
}
]
},
"criteria": {
"language": "text/cql",
"expression": "Numerator"
}
},
{
"code": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/measure-population",
"code": "denominator",
"display": "Denominator"
}
]
},
"criteria": {
"language": "text/cql",
"expression": "Denominator"
}
},
{
"code": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/measure-population",
"code": "denominator-exclusion",
"display": "Denominator Exclusion"
}
]
},
"criteria": {
"language": "text/cql",
"expression": "Denominator Exclusion"
}
}
]
}
],
"supplementalData": [
{
"code": {
"text": "sde-ethnicity"
},
"usage": [
{
"coding": [
{
"system": "http://hl7.org/fhir/measure-data-usage",
"code": "supplemental-data"
}
]
}
],
"criteria": {
"language": "text/cql",
"expression": "SDE Ethnicity"
}
},
{
"code": {
"text": "sde-payer"
},
"usage": [
{
"coding": [
{
"system": "http://hl7.org/fhir/measure-data-usage",
"code": "supplemental-data"
}
]
}
],
"criteria": {
"language": "text/cql",
"expression": "SDE Payer"
}
},
{
"code": {
"text": "sde-race"
},
"usage": [
{
"coding": [
{
"system": "http://hl7.org/fhir/measure-data-usage",
"code": "supplemental-data"
}
]
}
],
"criteria": {
"language": "text/cql",
"expression": "SDE Race"
}
},
{
"code": {
"text": "sde-sex"
},
"usage": [
{
"coding": [
{
"system": "http://hl7.org/fhir/measure-data-usage",
"code": "supplemental-data"
}
]
}
],
"criteria": {
"language": "text/cql",
"expression": "SDE Sex"
}
}
]
}